Subtype
Colorectal Adenocarcinoma
CI-CAN-00005002Explore in graph →
114 active trials1 approved drugs16 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005002Explore in graph →
Clinical trials
367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (54)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT05731271 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 111 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 |
| NCT06102902 | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06696768 | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07147231 | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | recruiting | Phase 1 | 411 | Inhibrx Biosciences, IncINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT05627635 | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05672316 | Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 28 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07658196 | TLR9 Immunotherapy for Peritoneal Carcinomatosis(TIPC) | recruiting | Phase 1 | 24 | Brown UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06225011 | Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer | recruiting | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04104139 | TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer | completed | Phase 1 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06834126 | Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial | recruiting | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07318805 | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 260 | PfizerINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04599140 | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02600949 | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | enrolling by invitation | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 47 | Emory UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer(DUO-CRC-NK-111) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | recruiting | Phase 1 | 22 | University of California, IrvineOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | suspended | Phase 1 / Phase 2 | 53 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02837263 | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | completed | Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04703101 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | recruiting | Phase 1 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT06336902 | Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | recruiting | Phase 1 | 15 | University of Southern CaliforniaOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04808323 | MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer | recruiting | Phase 1 | 22 | Medical College of WisconsinOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07462650 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | terminated | Phase 1 | 17 | Accent TherapeuticsINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04362839 | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | completed | Phase 1 | 39 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT04108481 | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer(iRE-C) | terminated | Phase 1 | 5 | University of IowaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04406857 | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer | terminated | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT04474470 | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer | completed | Phase 1 / Phase 2 | 52 | TyrNovo Ltd.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05130060 | A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer | completed | Phase 1 | 15 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | terminated | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | May 23, 2024 | clinicaltrials |
| NCT01447732 | Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 71 | Kyowa Kirin Co., Ltd.INDUSTRY | 0 | Apr 29, 2024 | clinicaltrials |
| NCT03373188 | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | completed | Phase 1 | 10 | Emory UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06195670 | Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC | not yet recruiting | Phase 1 / Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
Data updated 41 minutes agoSource updated Sep 30, 2026source: clinicaltrials